Skip to main content

Polymyalgia Rheumatica News

Related terms: Polymyalgia

Sarilumab Beneficial for Polymyalgia Rheumatica Patients

THURSDAY, Oct. 5, 2023 – For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the...

JAK Signaling May Be Behind Polymyalgia Rheumatica

MONDAY, July 10, 2023 – Janus tyrosine kinase (JAK) signaling may be involved in the pathogenesis of polymyalgia rheumatica (PMR), and tofacitinib may be an effective treatment, according to a pilot...

Kevzara (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica

Cambridge, MA and Tarrytown, N.Y. February 28, 2023. The U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory ...

Horizon Pharma Announces FDA Approval of Rayos (prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications

DEERFIELD, Ill., July 26, 2012 /PRNewswire/ – Horizon Pharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Rayos (prednisone) delayed-release tablets (1 mg, 2...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related drug support groups

prednisone, ibuprofen